ematology/Oncology, Director, Experimental Therapeutics Program 1120 15th Street BAA 5407 Augusta, GA 30912 E-mail: ORIXE@georgiahealth.edu

Rixe, Olivier, M.D.

2012-02-olivier-rixe

Director, Experimental Therapeutic Trials Program
Leader, Neuro-Oncology Multi-Disciplinary Clinic
Member, GRU Cancer Center
Professor of Medicine, Section of Hematology/Oncology

1120 15th Street, BAA-5407
Telephone:  706-721-2505
Fax:  706-721-5566
orixe@gru.edu

IFL Link | PubMed Link

 

Professional Overview

Dr. Rixe joined the Georgia Regents University Cancer Center in April 2012 to lead the Experimental Therapeutics Program and the multi-disciplinary Neuro-Oncology group while holding a Professor of Medicine position. Dr. Rixe received his medical degree from the Pierre and Marie Curie University of Paris, France in 1993, and completed four years of training in medical oncology and internal medicine in Paris.  At the National Institutes of Health National Cancer Institute’s (NCI) Medical Oncology Branch in Bethesda, Maryland he conducted one-year of laboratory research (1991-92). Dr. Rixe received his Ph.D. in molecular biology at Paris Diderot University, France in 2002.

Dr. Rixe is an internationally recognized medical oncologist in the field of developmental therapeutics.  Dr. Rixe has received numerous awards, including the prestigious Merit Order (Ordre National du Merite) for cancer research from the President
of France, Jacques Chirac.

Dr. Rixe has published approximately 150 publications in peer-reviewed journals. In academia he has held senior positions for the past 15 years conducting clinical trials in patients with resistant tumors. His research includes many translational studies.

Active in numerous drug trials, Dr. Rixe has been involved in the early phases of development for the U.S. Food and Drug Administration (FDA) approved agents, such as oxaliplatin, camptothecins, and taxanes, as well as targeted therapies including the antiangiogenic compounds sunitinib, axitinib and VEGF-trap.

He served as a senior medical oncologist at the renowned Pitie-Salpêtrière Hospital in Paris, and subsequently in the Phase 1 Unit at Gustave Roussy Institute in Villejuif, France. In 2003, Dr. Rixe was appointed Professor of Medical Oncology at Pierre and Marie Curie University. He joined the Medicine Oncology Branch at the NCI as a staff clinician in 2008.

At the University of Cincinnati as Professor of Medicine Dr. Rixe held the John and Gladys Strauss Chair in cancer research (2009). While at Cincinnati, he assumed the positions of Director of the Experimental Therapeutics Program and Deputy Director Division of Hematology/Oncology. From
2011-2012 he served a secondary appointment as Research Director of the UC Brain Tumor Center in the Department of Neurosurgery.

At GRU Dr. Rixe conducts several clinical trials and translational studies, including Phase 1 studies for solid tumors, new therapeutic strategies in recurrent glioblastomas, and the evaluation of new biomarkers in brain tumors.